Pacific Biosciences
PACB
#6498
Rank
โ‚น49.24 B
Marketcap
โ‚น167.31
Share price
2.07%
Change (1 day)
-79.67%
Change (1 year)

P/E ratio for Pacific Biosciences (PACB)

P/E ratio as of December 2024 (TTM): -1.56

According to Pacific Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.56299. At the end of 2022 the company had a P/E ratio of -5.84.

P/E ratio history for Pacific Biosciences from 2010 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-5.84-74.58%
2021-23.0-110.63%
2020216-2415.57%
2019-9.34-2.86%
2018-9.61223.99%
2017-2.97-35.21%
2016-4.58-85.01%
2015-30.5266.11%
2014-8.34102.53%
2013-4.12311.81%
2012-1.0000-27.5%
2011-1.381118.57%
2010-0.1132

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-5.14 228.68%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0297-98.10%๐Ÿ‡บ๐Ÿ‡ธ USA
19.7-1,357.56%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
34.1-2,283.24%๐Ÿ‡บ๐Ÿ‡ธ USA
15.0-1,057.56%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.